Group Leader
Maria Antònia Agustí Escasany
Principal Investigator (PI)
Mònica Sabaté Gallego, Immaculada Danés Carreras i Glòria Cereza García.
Researchers
Xavier Vidal Guitart, Cristina Aguilera Martín, Montserrat Bosch Ferrer, Núria Garcia Doladé, Carmen Asensio Ostos, Eulàlia Pérez Esquirol, Elena Ballarín Alins, Eduard Diogène Fadini, Lourdes Vendrell Bosch, Angela Mesas Idánez i Francisco Javier Medel Rebollo
PhD Students
Lina Camacho Arteaga, Jean-Marie Vianney Habarugia, Carolina Iglesias López, Kristopher Amaro Hosey, Lina Leguizamo, Carla Sans Pola, Judit Riera Arnau, Gustavo Molina Molina i Emilie Anderssen Nordalh
Nursing and Technical Staff
José J Barroso García i Montse Pérez González
28
PUBLICATIONS
195
IMPACT FACTOR
6.96
AVERAGE IMPACT FACTOR
SELECTED ARTICLES
Borobia AM, Carcas AJ, Pérez-Olmeda M, Castaño L, Bertran MJ, García-Pérez J, Campins M, Portolés A, González-Pérez M, García Morales MT, Arana-Arri E, Aldea M, Díez-Fuertes F, Fuentes I, Ascaso A, Lora D, Imaz-Ayo N, Barón-Mira LE, Agustí A, Pérez-Ingidua C, Gómez de la Cámara A, Arribas JR, Ochando J, Alcamí J, Belda-Iniesta C, Frías J; CombiVacS Study Group.
Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial.
Lancet. 2021 Jul 10;398(10295):121-130.
DOI: doi: 10.1016/S0140-6736(21)01420-3.
IF: 79.32
Iglesias-Lopez C, Agustí A, Vallano A, Obach M
Current landscape of clinical development and approval of advanced therapies.
Mol Ther Methods Clin Dev. 2021 Nov 11;23:606-618.
DOI: doi: 10.1016/j.omtm.2021.11.003.
IF: 6.70
Sabaté M, Vidal X, Ballarin E, Rottenkolber M, Schmiedl S, Grave B, Huerta C, Martin-Merino E, Montero D, Leon-Muñoz LM, Gasse C, Moore N, Droz C, Lassalle R, Aakjær M, Andersen M, De Bruin ML, Souverein P, Klungel OH, Gardarsdottir H, Ibáñez L.
Adherence to Direct Oral Anticoagulants in Patients With Non-Valvular Atrial Fibrillation: A Cross-National Comparison in Six European Countries (2008-2015).
Front Pharmacol. 2021 Nov 3;12:682890.
DOI: doi: 10.3389/fphar.2021.682890.
IF: 5.81
Aguilera C, Agustí A, Pérez E, Gracia RM, Diogène E, Danés I.
Spontaneously Reported Adverse Drug Reactions and Their Description in Hospital Discharge Reports: A Retrospective Study.
J Clin Med. 2021 Jul 26;10(15):3293.
DOI: doi: 10.3390/jcm10153293.
IF: 4.24
Amaro-Hosey K, Danés I, Vendrell L, Alonso L, Renedo B, Gros L, Vidal X, Cereza G, Agustí A.
Adverse Reactions to Drugs of Special Interest in a Pediatric Oncohematology Service.
Front Pharmacol. 2021 May 5;12:670945.
DOI: doi: 10.3389/fphar.2021.670945
IF: 5.81
Detección de falsos positivos en pacientes con alertas electrónicas de alergia a betalactámicos en las historias clínicas.
Principal Investigator: Victòria Cardona Dahl
Agency: ISCIII-FIS PI19/01656
Funding: 36,330€
Period: 2020-2022
Impact of EU label changes and revised pregnancy prevention programme for oral retinoid containing medicinal products: utilization and prescribing trends
Principal Investigator: Olaf Klungel, Miriam Sturkenboom
Agency: European Medicines Agency
Funding: 249,500 €
Period: 2020-2022
COVID-19 infection and medicines in pregnancy – a multinational registry based study (CONSIGN)
Principal Investigator: Miriam Sturkenboom, Olaf Klungel and Hedvig Nordeng
Agency: European Medicines Agency /2018/28PE (Lot4)
Funding: 548,890€
Period: 2020-2022
Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial
Principal Investigator: Magdalena Campins martí
Agency: Instituto de Salud Carlos III.
Funding: -
Period: 2021-2022
A phase IIB, double-blind, randomized, active controlled, multicentre, non-inferiority trial followed by a phase III, single-arm, open-label trial to assess immunogenicity and safety of a booster vaccination with a recombinant protein RBD fusion dimer candidate (PHH-1V) against SARS-CoV-2 in adults fully vaccinated against Covid-19 (HIPRA-HH-2).
Principal Investigator: Susana Otero Romero
Agency: HIPRA SCIENTIFIC, S.L.U
Funding: 200.620,8
Period: 2021-2022